Premature Ejaculation Clinical Trial
Official title:
A Prospective, Randomized, Double-blinded, Active-control, 3-Treatment Arm, Parallel, Multi-center, Phase 2 Trial to Evaluate Safety and Efficacy With CDFR0812-15/25mg and CDFR0812-15/50mg Compared to Clomipramine HCl 15mg in Male Patients Diagnosed With Premature Ejaculation
The purpose of this study is to evaluate the safety and efficacy of on-demand therapy with CDFR0812-15/25mg and CDFR0812-15/50mg compared to on-demand therapy with single-drug administration of Clomipramine HCl 15mg in Korean Male Patients Diagnosed with Premature Ejaculation
Clomipramine is a dibenzazepine-derivative tricyclic antidepressant (TCA) and is a potent
inhibitor of serotonin and norepinephrine reuptake. Clomipramine may be used in a variety of
indications. Condencia Tab contains low dose of 15mg of clomipramine HCl as an active
ingredient, which is newly approved to market for the treatment of premature ejaculation.
This study is a prospective, randomized, double-blinded, active-control, 3-treatment arm,
parallel, multi-center clinical trial. Approximately a total of 297 male patients diagnosed
with premature ejaculation will be enrolled and randomized into 3 groups (99 subjects per a
group).
The efficacy of oral administration of Clomipramine HCl will be investigated closely
compared to the effects after oral administration of CDFR0812-15/25mg and CDFR0812-15/50mg.
The secondary object is to investigate general safety of oral administration of
CDFR0812-15/25mg and CDFR0812-15/50mg.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02232425 -
IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)
|
Phase 2 | |
| Completed |
NCT01439984 -
Trial of PED-1 in Male Patients With Premature Ejaculation
|
Phase 3 | |
| Completed |
NCT01184105 -
A Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment of Premature Ejaculation
|
Phase 1 | |
| Completed |
NCT01203202 -
Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation
|
Phase 2 | |
| Completed |
NCT03942367 -
Evaluation of the Safety and Effectiveness of the vPatch Device
|
N/A | |
| Completed |
NCT02939495 -
The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy
|
Phase 4 | |
| Completed |
NCT02572037 -
Research and Clinical Value of New Classification for Premature Ejaculation: Multi-Center Research
|
||
| Recruiting |
NCT02581826 -
Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation
|
Phase 2 | |
| Terminated |
NCT00983736 -
Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation
|
Phase 3 | |
| Completed |
NCT00556478 -
Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation
|
Phase 2/Phase 3 | |
| Completed |
NCT00549211 -
A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.
|
Phase 1 | |
| Not yet recruiting |
NCT05556083 -
Sildenafil Added Effect in Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE)
|
Phase 2 | |
| Completed |
NCT03304808 -
Efficacy of a New Behavioral Treatment for Premature Ejaculation Using a Masturbation Aid Device: Star-Stop 3.0
|
N/A | |
| Completed |
NCT00861484 -
Proof of Mechanism in ELT
|
Phase 1 | |
| Completed |
NCT02984592 -
Effect of Exercise on Premature Ejaculation
|
N/A | |
| Completed |
NCT03174470 -
Safety Demonstration of Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
|
N/A | |
| Completed |
NCT02794454 -
A Study to Evaluate Efficacy of Investigational Product HeezOn Ultra -1/ HeezOn Ultra-2 on Male Sexual Health
|
N/A | |
| Completed |
NCT02297152 -
A New Treatment for Premature Ejaculation?
|
N/A | |
| Not yet recruiting |
NCT00656552 -
Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation
|
Phase 0 | |
| Recruiting |
NCT04703127 -
Effectiveness and Tolerability of the On-demand Use of Combined Dapoxetine With Tadalafil and Combined Dapoxetine With Lidocaine 5% Spray in Treatment of Patients With Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.
|
Phase 3 |